Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C

Journal of Clinical Virology

Volumn 56, Issue 3, 2013, Pages 291-295

  Loggi, Elisabetta ^a   Cursaro, Carmela ^a   Scuteri, Alessandra ^a   Grandini, Elena ^a   Panno, Arianna Martello ^a   Galli, Silvia ^b   Furlini, Giuliano ^b   Bernardi, Mauro ^a   Galli, Claudio ^c   Andreone, Pietro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c ABBOTT DIAGNOSTICS   (Italy)

Author keywords

Chronic hepatitis C; HCV RNA; HCVAg; Kinetics; Monitoring; Treatment outcomes

Indexed keywords

HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; HEPATITIS C VIRUS RNA; KETOPROFEN; PEGINTERFERON ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ACCURACY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HEPATITIS C; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

EID: 84872871883     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.11.012     Document Type: Article

References (30)

1. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374. 11.
2. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264.
3. McHutchinson J.G., Lawitz E.J., Schiffman M.L., Muir A.J., Galler G.W., McCone J., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
4. Ferenci P., Laferl H., Scherzer T.M., Gschwantler M., Maieron A., Brunner H., et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008, 135:451-458.
5. Mederacke I., Wedemeyer H., Cieseka S., Steinmann E., Raupacha R., Wursthorn K., et al. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009, 46:210-215.
6. Ross R.S., Viazov S., Salloum S., Hilgard P., Gerken G., Roggendorf M. Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol 2010, 48:1161-1168.
7. Moscato G.A., Giannelli G., Grandi B., Pieri D., Marsi O., Guarducci I., et al. Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C. Intervirology 2011, 54:61-65.
8. Medici M.C., Furlini G., Rodella A., Fuertes A., Monachetti A., Calderaro A., et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 2011, 51:260-265.
9. Kesli P., Polat H., Terzi Y., Kurtoglu M.G., Uyar Y. Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-HCV results. J Clin Microbiol 2011, 49:4089-4093.
10. Gramenzi A., Cursaro C., Margotti M., Balsano C., Spaziani A., Anticoli S., et al. Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. World J Gastroenterol 2009, 15:5946-5952.
11. Morota K., Fujinami R., Kinukawa H., Machida T., Ohno K., Saegusa H., et al. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods 2009, 157:8-14.
12. Sagnelli E., Stroffolini T., Mele A., Almasio P., Coppola N., Ferrigno L., et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 2005, 75:522-527.
13. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
14. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
15. Marcellin P., Rizzetto M. Response-guided therapy: optimizing treatment now and in the future. Antiviral Ther 2008, Suppl. 1:1-2.
16. Durante-Mangoni E., Zampino R., Portella G., Adinolfi R.E., Utili R., Ruggiero G. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Clin Inf Dis 2009, 49:498-506.
17. Nomura H., Miyagi Y., Tanimoto H., Higashi M., Ishibashi H. Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. J Gastroenterol 2009, 44:338-345.
18. Martinot-Peignoux M., Khiri H., Leclere L., Maylin S., Marcellin P., Halfon P. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C. J Clin Virol 2009, 46:216-221.
19. Chevaliez S. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect 2011, 117:116-121.
20. Icardi G., Ansaldi F., Bruzzone B.M., Durando P., Lee S., De Luigi C., et al. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. J Clin Microbiol 2001, 39:3110-3114.
21. Bouvier-Alias M., Patel K., Dahari H., Beaucourt S., Larderie P., Blatt L., et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002, 36:211-218.
22. Takahashi M., Saito H., Higashimoto M., Atsukawa K., Ishii H. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol 2005, 43:186-191.
23. Sasase N., Kim S.R., Kim K.I., Taniguchi M., Imoto S., Mita K., et al. Usefulness of a new immunoradiometric assay of HCV Core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b. Intervirology 2008, 51:70-75.
24. Fujino T., Nakamuta N., Aoyagi Y., Fukuizumi K., Takemoto R., Yoshimoto T., et al. Early decline of the HCV core antigen can predict SVR in patients with HCV treated by pegylated interferon plus ribavirin combination therapy. J Dig Dis 2009, 10:21-25.
25. Schuettler C.G., Thomas C., Discher T., Friese G., Lohmeyer J., Schuster R., et al. Variable ratio of hepatitis C virus RNA to viral core antigen in patient sera. J Clin Microbiol 2005, 42:1977-1981.
26. Poordad F.F., Flamm S.L. Virological relapse in chronic hepatitis C. Antiviral Ther 2009, 14:303-313.
27. Deltenre P., Canva V., El Nady M., Francois C., Castelain S., Dharancy S. A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study. J Viral Hepatitis 2009, 16:500-505.
28. Descamps V., Op de Beck A., Plassart C., Brochot E., Francois C., Elle F., et al. Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients. J Clin Microbiol 2012, 50:465-468.
29. Dahari H., Shudo E., Cotler S.J., Layden T.L., Perelson A.S. Modeling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antiviral Ther 2009, 14:459-464.
30. Gastaminza P., Dryden K.A., Boyd B., Wood M.R., Law M., Yeager M., et al. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol 2010, 84:10999-11009.